George Kaiser Family Foundation Buys New Shares in MaxCyte, Inc. $MXCT

George Kaiser Family Foundation bought a new position in shares of MaxCyte, Inc. (NASDAQ:MXCT) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 627,536 shares of the company’s stock, valued at approximately $772,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Capricorn Fund Managers Ltd bought a new position in shares of MaxCyte in the first quarter valued at $5,760,000. Vitruvian Partners LLP acquired a new stake in shares of MaxCyte during the 2nd quarter valued at $6,203,328,000. BlackRock Inc. bought a new stake in shares of MaxCyte during the 2nd quarter worth $3,765,000. State Street Corp boosted its stake in shares of MaxCyte by 4.0% during the 4th quarter. State Street Corp now owns 2,358,384 shares of the company’s stock worth $3,655,000 after acquiring an additional 91,534 shares in the last quarter. Finally, AXA S.A. grew its holdings in shares of MaxCyte by 123.2% in the 2nd quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock worth $4,801,000 after acquiring an additional 1,215,481 shares during the last quarter. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Price Performance

MXCT stock opened at $1.38 on Friday. The firm has a market capitalization of $142.43 million, a P/E ratio of -4.18 and a beta of 1.48. MaxCyte, Inc. has a 52-week low of $0.64 and a 52-week high of $1.86. The company’s 50 day simple moving average is $1.22 and its 200-day simple moving average is $0.99.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. MaxCyte had a negative net margin of 114.77% and a negative return on equity of 18.92%. The firm had revenue of $6.50 million during the quarter, compared to analyst estimates of $6.51 million. Sell-side analysts predict that MaxCyte, Inc. will post -0.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MXCT has been the topic of a number of recent analyst reports. Wall Street Zen raised MaxCyte from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings lowered MaxCyte from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $5.00.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.